Braveheart Bio, Inc. (BRVE) Stock

NASDAQ: BRVEHealthcare company in the biotechnology industry, based in San Francisco, CA.

Braveheart Bio stock price chart

BRVE interactive chart →

BRVE stock quote & key statistics

Braveheart Bio earnings per share

Income →
Earnings per share

Braveheart Bio revenue & net income

Income →
RevenueNet income

Braveheart Bio annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$66.1M—

Fiscal year ending December 31. Source: company filings via EODHD.

About Braveheart Bio, Inc.

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Braveheart Bio stock FAQ

What is the Braveheart Bio stock ticker symbol?

Braveheart Bio, Inc. trades on the NASDAQ under the ticker symbol BRVE.

What sector and industry is Braveheart Bio in?

Braveheart Bio, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Braveheart Bio have?

Braveheart Bio, Inc. has about 49 full-time employees.

What were Braveheart Bio's revenue and earnings last fiscal year?

Braveheart Bio reported revenue of $0 and net income of -$66.1M in fiscal 2025.

When did Braveheart Bio go public?

Braveheart Bio stock began trading on August 6, 2026.

Biotechnology stocks

All Healthcare stocks →